Amgen: EPS up 13% in Q3

(CercleFinance.com) - Amgen on Wednesday evening reported Q3 2024 adjusted EPS up 13% to $5.
58, with a non-GAAP operating margin down 2.4 points to 49.6%, while revenues rose 23% to $8.5bn. NB: pmt +1.7%.

Product sales increased 24%, with volume growth of 29% but a 2% decline in net prices. Excluding Horizon Therapeutics, they grew by 8%, supported by volume growth of 12%.

For FY 2024, the healthcare group now expects adjusted EPS (non-GAAP) of between $19.20 and $20 (instead of $19.10 to $20.10) and revenues of between $33bn and $33.8bn (instead of $32.8bn to $33.8bn).


Copyright (c) 2024 CercleFinance.com. All rights reserved.